Business Context and Reporting Period
Cellebrite DI Ltd. (Nasdaq: CLBT) is an Israeli company providing AI-powered digital investigative and intelligence solutions for legally sanctioned investigations. The filing is an Annual Report on Form 20-F for the fiscal year ended December 31, 2025. The company operates as a single reporting segment and is a "foreign private issuer" under U.S. securities laws.
Key Financial Metrics
| Metric (in millions, except per share) | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $475.7 | $401.2 | +19% |
| Gross Profit | $400.5 | $338.6 | +18% |
| Gross Margin | 84% | 84% | - |
| Operating Income | $66.5 | $56.9 | +17% |
| Net Income (Loss) | $78.3 | $(283.0) | $361.3M improvement |
| Diluted EPS | $0.31 | $(1.35) | - |
| Adjusted EBITDA | $127.6 | $99.4 | +28% |
| Free Cash Flow | $160.3 | $123.6 | +30% |
| Cash & Equivalents | $124.5 | $191.7 | - |
| Total Liquidity (Cash, Deposits, Securities) | $535.0 | $483.8 | - |
| Debt | $0 | $0 | - |
Material Changes vs. Prior Period
- Profitability Turnaround: The company returned to profitability with a net income of $78.3 million in 2025, compared to a net loss of $283.0 million in 2024. This swing was primarily driven by the reclassification of derivative liabilities (Warrants, Restricted Sponsor Shares, and Price Adjustment Shares) from liabilities to equity in late 2024, eliminating significant fair value remeasurement expenses that impacted the 2024 financial results.
- Revenue Growth: Revenue grew 19% year-over-year, driven by continued adoption of the Inseyets digital forensics suite and expanded usage of analytics tools like Pathfinder and Guardian by existing customers.
- Acquisitions: In December 2025, Cellebrite acquired Corellium, Inc. for approximately $156 million (cash and contingent consideration) to expand its virtualization software capabilities. In March 2026 (subsequent event), the company acquired SCG Canada Inc. for approximately $17 million.
- Operating Expenses: Total operating expenses increased 19% to $334.0 million, with Research and Development rising 16% and Sales and Marketing rising 17%, reflecting continued investment in AI capabilities and go-to-market expansion.
Guidance, Outlook, and Risks
Outlook and Strategy: Management expects to expand business through new logo wins, upgrades, and price increases. Key strategic initiatives include converting legacy customers to the Inseyets platform, achieving FedRAMP authorization for Guardian Forensics to sell to U.S. Federal agencies, and leveraging the Corellium acquisition for defense and intelligence verticals. The company anticipates strong demand driven by the increasing digital nature of crime and geopolitical tensions.
Key Risks and Contingencies:
- Geopolitical Instability: Operations are heavily concentrated in Israel. Ongoing conflicts (Israel-Hamas, tensions with Iran) pose risks to employee safety, business continuity, and supply chains. Approximately 32% of expenses are denominated in Israeli New Shekels (NIS), creating foreign exchange exposure.
- Regulatory and Export Controls: The company is subject to Israeli export laws and U.S. sanctions. A new Israeli export regime effective March 2026 may impose stricter licensing requirements. Compliance with evolving AI regulations (e.g., EU AI Act) and data privacy laws (GDPR) is critical.
- Customer Concentration: Over 90% of revenue comes from public sector customers (law enforcement, defense, intelligence). This exposes the company to government budget cycles, appropriations delays, and potential contract terminations.
- Technology and Competition: Risks include the inability to keep pace with device encryption updates from OEMs, potential errors in AI algorithms, and intense competition from larger vendors.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the 19% revenue growth and the dollar-based net retention rate (116% in 2025) given the heavy reliance on government budget cycles.
- Acquisition Integration: Assess the integration progress and revenue contribution of the Corellium acquisition and the subsequent SCG Canada acquisition.
- Geopolitical Exposure: Monitor the impact of the Israel-Hamas conflict and regional tensions on operations, employee availability (military reserve duty), and supply chain stability.
- Regulatory Compliance: Review the status of the new Israeli export license regime and any potential impacts on sales to specific jurisdictions.
- Non-GAAP Reconciliation: Scrutinize the reconciliation of Net Income to Adjusted EBITDA, specifically the treatment of share-based compensation ($44.9 million in 2025) and acquisition-related costs.